Temisis Therapeutics announced that it has received 1.6 million in a round of funding on December 18, 2020. The transaction included participation from returning investor Plant Advanced Technologies SA (ENXTPA:ALPAT) and new investor Financiere Hoche Bains-Les-Bains SA (ENXTPA:MLHBB). As part of the transaction, Financiere Hoche Bains-Les-Bains SA (ENXTPA:MLHBB) acquired 1.54% stake in the company and Plant Advanced Technologies SA (ENXTPA:ALPAT) now holds 98.46% in the company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.5 EUR | 0.00% | +2.94% | +24.26% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+24.26% | 12.18M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ALPAT Stock
- News Plant Advanced Technologies
- Temisis Therapeutics announced that it has received €1.6 million in funding from Financiere Hoche Bains-Les-Bains SA, Plant Advanced Technologies SA